Rhythm Biosciences goes out of tune
Cancer test developer Rhythm Biosciences’ shares plunged on the ASX yesterday when the company withdrew an application for registration with the Therapeutic Goods Administration of its ColoSTAT test for colorectal cancer. The company’s shares closed down 38 percent to 36.5 cents last night after the company announced its response to its application for an Australian…